AUTHORS
Federico Simonetta, MD, PhD, Antonio Pierini, MD, PhD2, Juana Schwartz Mota3, Matthias Edinger, MD4, Joao Lacerda5, Jose Antonio Perez-Simon, MD, PhD6, Mauro Di Ianni7, Mario Arpinati Sr8, Alexandros Spyridonidis9, Eva Wagner Drouet10, Frederic Baron11, Pietro Merli Jr, MD12, Tayfun Güngör13, Jeroen Knippenberg14, Nicole Santoro15, Moniek de Dewitte, MD, PhD16, Florent Malard, MD, PhD17, Simona Pagliuca, MD,PhD18, Jurgen Kuball, MD19, Annalisa Ruggeri, MD20
AFFILIATIONS
1 Hôpitaux Universitaires de Genève, Geneva, Switzerland
2 University of Perugia, Perugia, Italy
3 EBMT Leiden Study Unit, Leiden, Netherlands
4 University Hospital Regensburg, Regensburg, Germany
5 GIMM-Gulbenkian Institute for Molecular Medicine, Lisboa, Portugal, ULS Santa Maria, Faculdade de Medicina, Universidade de Lisboa, Lisboa, Portugal
6 Department of Hematology, University Hospital Virgen del Rocio, Instituto de Biomedicina de Sevilla (IBIS) / CSIC, Universidad de Sevilla, Sevilla, Spain
7 Department of Medicine and Aging Sciences, University of Chieti-Pescara, Pescara, Italy, Hematology with BMT Unit, Pescara Hospital, Pescara, Italy
8 IRCCS AOU Bologna, 'Seragnoli', Institute of Hematology, Bologna, Italy
9 Hematology Division, Department of Internal Medicine, University of Patras, Medical School, Patras, Greece
10 University Medical Center Mainz, Mainz, Germany
11 University of Liège, Liège, Belgium
12 Bambino Gesù Children's Hospital, Rome, Italy
13 University Children's Hospital Zurich, Zurich, Switzerland
14 EBMT Leiden Study Unit, Leiden, Netherlands
15 Hematology with BMT Unit, Pescara Hospital, Pescara, Italy
16 University Medical Center Utrecht, Utrecht, Netherlands
17 Hôpital Saint-Antoine, AP-HP, Sorbonne Université, Paris, France
18 CHRU NANCY, Vandœuvre-lès-Nancy, France
19 University Medical Centre Utrecht, Utrecht, Netherlands
20 San Raffaele Scientific Institute, Milan, Italy
ABSTRACT
Background: CD4⁺CD25⁺FOXP3⁺ regulatory T cells (Tregs) are a specialized subset of T lymphocytes that play a central role in maintaining immune tolerance and have emerged as a promising cellular therapy for the prevention and treatment of graft-versus-host disease (GVHD) following allogeneic hematopoietic stem cell transplantation (allo-HCT). The recent FDA approval of the first CD4⁺CD25⁺FOXP3⁺ Treg-based cellular therapy for GVHD prevention marks a major milestone following decades of pioneering clinical research, including important contributions from European transplant centers. We therefore conducted an EBMT survey to characterize the clinical experience and current practices of European centers using CD4⁺CD25⁺FOXP3⁺ Tregs.
Methods: An EBMT survey was distributed to European transplant centers with clinical experience using CD4⁺CD25⁺FOXP3⁺ Tregs. Data were collected on Treg manufacturing, product characterization and quality control, donor and cell source, transplantation platform, clinical indications, and treatment protocols.
Results: Eleven centers from Italy, Germany, Spain, Portugal, Switzerland, Belgium, and Greece reported clinical experience with Treg therapy for GVHD. Two centers used in vitro-generated regulatory T-cell products distinct from classical CD4⁺CD25⁺FOXP3⁺ Tregs and were therefore excluded from subsequent analyses. The remaining nine centers reported treatment of 455 patients, including 416 adults and 39 pediatric patients. Five centers used CD4⁺CD25⁺FOXP3⁺ Tregs exclusively within clinical trials, three exclusively as standard of care, and one in both settings. Three centers employed Tregs exclusively for GVHD prophylaxis, five exclusively for the treatment of established GVHD (chronic in all centers and acute in one center), and one for both indications. Fresh, unmanipulated Tregs were used by most centers and isolated by immunomagnetic enrichment, most commonly through CD8/CD19 depletion followed by CD25-positive selection. One center employed ex vivo expanded Tregs after magnetic enrichment and FACS sorting of CD25⁺CD127lowCD45RA⁺ cells. Tregs were predominantly collected from dedicated unstimulated donor leukapheresis, although three centers also used G-CSF-mobilized peripheral blood stem cell collections. Product quality was primarily assessed by flow cytometry based on CD25, CD127, and FOXP3 expression, with purity thresholds ranging from none to >90%. Cryopreservation was rarely employed, with only one center reporting routine use. All centers used matched sibling donors, while selected centers also included matched and mismatched unrelated donors, as well as haploidentical donors. Prophylactic Tregs were generally administered at the time of transplantation, most commonly following the Perugia protocol consisting of Treg infusion before conventional T-cell infusion without pharmacologic GVHD prophylaxis. Therapeutic Tregs were primarily used for steroid-refractory chronic GVHD, most commonly as third-line therapy in combination with ruxolitinib and/or calcineurin inhibitors. Nearly all centers administered a single Treg infusion, with only one center reporting administration of up to three doses in the therapeutic setting.
Conclusions: European transplant centers have accumulated one of the largest worldwide experiences with CD4⁺CD25⁺FOXP3⁺ regulatory T-cell therapy for GVHD prevention and treatment. Although manufacturing procedures and clinical implementation remain heterogeneous, several common practices have emerged with respect to cell processing, product characterization, and clinical application. These findings provide the first comprehensive overview of contemporary European practice in Treg use for GvHD and establish a foundation for harmonization, collaborative clinical studies, and the continued development of CD4⁺CD25⁺FOXP3⁺ Treg-based therapies within the EBMT.
DISCLOSURES
Federico Simonetta, MD, PhD: No relevant conflicts of interest to declare.